nitrendipine has been researched along with Electrolytes in 8 studies
Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.
nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.
Electrolytes: Substances that dissociate into two or more ions, to some extent, in water. Solutions of electrolytes thus conduct an electric current and can be decomposed by it (ELECTROLYSIS). (Grant & Hackh's Chemical Dictionary, 5th ed)
Excerpt | Relevance | Reference |
---|---|---|
"Thirty patients with moderate to severe hypertension (diastolic blood pressure greater than or equal to 115 mmHg), after a run-in wash out period of 15 days, were treated with muzolimine at a dosage of 20 mg once daily, given at 1 p." | 9.05 | Muzolimine and nitrendipine in the treatment of arterial hypertension. ( de Divitiis, O; Di Somma, S; Fazio, S; Galderisi, M; Iacono, C; Petitto, M, 1985) |
"Thirteen patients with hypertension and normal renal function received nitrendipine, a calcium entry blocker." | 7.67 | Nitrendipine, a calcium-entry blocker. Renal and humoral effects in human arterial hypertension. ( Bravo, EL; Fouad, FM; Pedrinelli, R; Tarazi, RC; Textor, SC, 1986) |
"To investigate the pathogenetic constellation and its modification by calcium channel blockade in hypertension associated with chronic nonoliguric renal failure, blood pressure (BP), various pressor factors or correlates, cardiovascular responsiveness, and plasma atrial natriuretic peptide (ANP) were assessed in 15 hypertensive patients (serum creatinine 160-715 mumol/l) before and after 6 weeks of intervention with the agent nitrendipine." | 5.06 | Hypertensive dysregulation and its modification by calcium channel blockade in nonoliguric renal failure. ( Bürgisser, E; Ferrier, C; Gnädinger, MP; Jahn, H; Schohn, D; Weidmann, P, 1989) |
"Thirty patients with moderate to severe hypertension (diastolic blood pressure greater than or equal to 115 mmHg), after a run-in wash out period of 15 days, were treated with muzolimine at a dosage of 20 mg once daily, given at 1 p." | 5.05 | Muzolimine and nitrendipine in the treatment of arterial hypertension. ( de Divitiis, O; Di Somma, S; Fazio, S; Galderisi, M; Iacono, C; Petitto, M, 1985) |
"Thirteen patients with hypertension and normal renal function received nitrendipine, a calcium entry blocker." | 3.67 | Nitrendipine, a calcium-entry blocker. Renal and humoral effects in human arterial hypertension. ( Bravo, EL; Fouad, FM; Pedrinelli, R; Tarazi, RC; Textor, SC, 1986) |
"Nitrendipine-treated intact rats excreted slightly more water and Na+ and less K+ than controls, but none of the differences were significant statistically." | 1.27 | Effect of nitrendipine on urine volume, osmolality, and electrolyte excretion in normal, adrenal-enucleate, and mononephrectomized rats. ( Hall, CE; Hungerford, S, 1984) |
"Nitrendipine was also phosphaturic and calciuric but did not alter acid excretion." | 1.27 | Renal hemodynamic and tubular transport effects of nitrendipine. ( Greenberg, A; Puschett, JB; Wallia, R, 1985) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 6 (75.00) | 18.7374 |
1990's | 2 (25.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hall, CE | 1 |
Hungerford, S | 1 |
Gilar, M | 1 |
Uhrová, M | 1 |
Tesarová, E | 1 |
Singh, J | 1 |
Kaur, AH | 1 |
Bansal, S | 1 |
Lal, H | 1 |
Weidmann, P | 1 |
Schohn, D | 1 |
Gnädinger, MP | 1 |
Bürgisser, E | 1 |
Ferrier, C | 1 |
Jahn, H | 1 |
Stimpel, M | 1 |
Neyses, L | 1 |
Locher, R | 1 |
Knorr, M | 1 |
Vetter, W | 1 |
Pedrinelli, R | 1 |
Fouad, FM | 1 |
Tarazi, RC | 1 |
Bravo, EL | 1 |
Textor, SC | 1 |
Wallia, R | 1 |
Greenberg, A | 1 |
Puschett, JB | 1 |
de Divitiis, O | 1 |
Di Somma, S | 1 |
Petitto, M | 1 |
Galderisi, M | 1 |
Iacono, C | 1 |
Fazio, S | 1 |
2 trials available for nitrendipine and Electrolytes
Article | Year |
---|---|
Hypertensive dysregulation and its modification by calcium channel blockade in nonoliguric renal failure.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Blood Pressure; Calcium Channel Blockers; Catecholamines; | 1989 |
Muzolimine and nitrendipine in the treatment of arterial hypertension.
Topics: Adult; Blood Pressure; Calcium Channel Blockers; Captopril; Clinical Trials as Topic; Double-Blind M | 1985 |
6 other studies available for nitrendipine and Electrolytes
Article | Year |
---|---|
Effect of nitrendipine on urine volume, osmolality, and electrolyte excretion in normal, adrenal-enucleate, and mononephrectomized rats.
Topics: Adrenalectomy; Animals; Calcium Channel Blockers; Diuresis; Electrolytes; Female; Glomerular Filtrat | 1984 |
Enantiomer separation of dihydropyridine calcium antagonists with cyclodextrins as chiral selectors: structural correlation.
Topics: Amlodipine; Buffers; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Cyclodextrins; | 1996 |
Effect of nitrendipine, nimodipine and nisoldipine on water and electrolytes excretion in rats.
Topics: Animals; Calcium Channel Blockers; Creatinine; Diuresis; Electrolytes; Female; Glomerular Filtration | 1996 |
High density lipoproteins--modulators of the calcium channel?
Topics: Adult; Calcium; Calcium Channels; Cholesterol; Electrolytes; Erythrocytes; Humans; In Vitro Techniqu | 1985 |
Nitrendipine, a calcium-entry blocker. Renal and humoral effects in human arterial hypertension.
Topics: Adult; Aged; Aldosterone; Blood Volume; Body Fluids; Calcium Channel Blockers; Catecholamines; Elect | 1986 |
Renal hemodynamic and tubular transport effects of nitrendipine.
Topics: Administration, Oral; Diuresis; Electrolytes; Glomerular Filtration Rate; Humans; Infusions, Parente | 1985 |